CDH23 Gene Deafness Autosomal Recessive Type 12 Genetic Test
Components
- Test Name: CDH23 Gene Deafness Autosomal Recessive Type 12 Genetic Test
- Price: 4400.0 AED
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test Type: Ear Nose Throat Disorders
- Doctor: ENT Doctor
- Test Department: Genetics
Pre Test Information
Clinical History of Patient who is going for IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test gene IARS7.
Test Details
The CDH23 gene is associated with a type of deafness known as autosomal recessive type 12 (DFNB12). This genetic condition is characterized by progressive hearing loss that typically begins in childhood or adolescence. NGS (Next-Generation Sequencing) genetic testing is a method used to analyze multiple genes simultaneously. In the context of CDH23 gene deafness, an NGS genetic test would involve sequencing the CDH23 gene to identify any genetic variations or mutations that may be causing or contributing to the individual’s hearing loss. The results of an NGS genetic test for CDH23 gene deafness can help in confirming a diagnosis, providing information about the specific genetic mutation causing the condition, and determining the inheritance pattern. This information can be useful for genetic counseling, family planning, and potentially guiding treatment options or interventions for managing the hearing loss.
Test Name | CDH23 Gene Deafness autosomal recessive type 12 Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Ear Nose Throat Disorders |
Doctor | ENT Doctor |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test gene IARS7 |
Test Details |
The CDH23 gene is associated with a type of deafness known as autosomal recessive type 12 (DFNB12). This genetic condition is characterized by progressive hearing loss that typically begins in childhood or adolescence. NGS (Next-Generation Sequencing) genetic testing is a method used to analyze multiple genes simultaneously. In the context of CDH23 gene deafness, an NGS genetic test would involve sequencing the CDH23 gene to identify any genetic variations or mutations that may be causing or contributing to the individual’s hearing loss. The results of an NGS genetic test for CDH23 gene deafness can help in confirming a diagnosis, providing information about the specific genetic mutation causing the condition, and determining the inheritance pattern. This information can be useful for genetic counseling, family planning, and potentially guiding treatment options or interventions for managing the hearing loss. |